← Back to Screener
Dianthus Therapeutics, Inc. Common Stock (DNTH)
Price$91.92
Favorite Metrics
Price vs S&P 500 (26W)161.89%
Price vs S&P 500 (4W)10.44%
Market Capitalization$5.00B
All Metrics
Book Value / Share (Quarterly)$11.42
P/TBV (Annual)1.61x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.99
Price vs S&P 500 (YTD)122.17%
Net Profit Margin (TTM)-7973.33%
EPS (TTM)$-4.11
10-Day Avg Trading Volume0.72M
EPS Excl Extra (TTM)$-4.11
EPS (Annual)$-4.20
ROI (Annual)-32.90%
Cash / Share (Quarterly)$9.35
Revenue Growth QoQ (YoY)-78.58%
ROA (Last FY)-30.58%
Revenue Growth TTM (YoY)-67.35%
EBITD / Share (TTM)$-4.63
ROE (5Y Avg)-39.22%
Operating Margin (TTM)-8739.34%
Cash Flow / Share (Annual)$-2.99
P/B Ratio10.14x
P/B Ratio (Quarterly)3.58x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)2433.13x
Net Interest Coverage (TTM)-57.94x
ROA (TTM)-36.42%
EPS Incl Extra (Annual)$-4.20
Current Ratio (Annual)13.32x
Quick Ratio (Quarterly)13.16x
3-Month Avg Trading Volume0.96M
52-Week Price Return391.36%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$12.04
P/S Ratio (Annual)2458.22x
Asset Turnover (Annual)0.00x
52-Week High$96.50
EPS Excl Extra (Annual)$-4.20
CapEx CAGR (5Y)-11.84%
Tangible BV CAGR (5Y)16.06%
26-Week Price Return170.63%
Quick Ratio (Annual)13.16x
13-Week Price Return101.47%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)13.32x
Enterprise Value$4,953.844
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)3.60%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-7973.33%
Cash / Share (Annual)$9.35
3-Month Return Std Dev73.69%
Net Income / Employee (TTM)$-2
ROE (Last FY)-32.90%
EPS Basic Excl Extra (Annual)$-4.20
Receivables Turnover (TTM)4.74x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.11
ROI (TTM)-38.85%
P/S Ratio (TTM)2458.22x
Revenue / Share (Annual)$0.05
Tangible BV / Share (Annual)$27.96
Price vs S&P 500 (52W)356.26%
Year-to-Date Return126.30%
5-Day Price Return3.62%
EPS Normalized (Annual)$-4.20
ROA (5Y Avg)-33.44%
Net Profit Margin (Annual)-7973.33%
Month-to-Date Return11.13%
Cash Flow / Share (TTM)$-14.53
EBITD / Share (Annual)$-4.63
Operating Margin (Annual)-8739.34%
ROI (5Y Avg)-39.22%
EPS Basic Excl Extra (TTM)$-4.11
P/TBV (Quarterly)0.96x
P/B Ratio (Annual)3.58x
Pretax Margin (TTM)-7973.33%
Book Value / Share (Annual)$11.42
Price vs S&P 500 (13W)98.60%
Beta1.24x
Revenue / Share (TTM)$0.05
ROE (TTM)-38.85%
52-Week Low$16.64
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.38
4.38
4.38
4.41
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
DNTHDianthus Therapeutics, Inc. Common Stock | 2458.22x | -67.35% | — | — | $91.92 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Dianthus Therapeutics is a clinical-stage biotechnology company developing next-generation monoclonal antibody therapies targeting complement for severe autoimmune and inflammatory diseases. The company's lead candidate, DNTH103, is a subcutaneous C1s inhibitor designed to offer improved selectivity and potency over existing complement therapies. The team brings substantial biotechnology and pharmaceutical expertise to advance its pipeline.